RIPK3 and metabolic dysfunction-associated steatohepatitis: Deletion of RIPK3, intraperitoneal injection of antisense oligonucleotides targeting RIPK3, and dabrafenib treatment have been shown to exert hepatoprotective effects in mouse models of acetaminophen toxicity, concanavalin hepatitis A, alcohol and diet intoxication, and NASH [94].